UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
EMERYVILLE, Calif., March 06, 2018 -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that company management is scheduled to present at two upcoming investor conferences:
- Gregory T. Went, Ph.D., the company’s Founder, Chairman and Chief Executive Officer, is scheduled to present at the Cowen and Company 38th Annual Health Care Conference on Monday, March 12, 2018 at 3:30 p.m. ET
- Richard A. King, the company’s Chief Operating Officer, is scheduled to present at the 17th Annual Needham Healthcare Conference on Tuesday, March 27, 2018 at 9:00 a.m. ET
The presentations will be webcast live from the investor relations section of the Adamas website at http://ir.adamaspharma.com/events.cfm. Archived versions of the webcasts will be available via replay for 30 days following the presentations.
About Adamas Pharmaceuticals, Inc.
Adamas is using its deep understanding of time-dependent biology to redefine the treatment experience for patients suffering from chronic neurological diseases. The company is building upon the commercial launch of GOCOVRI™ (amantadine) extended release capsules (previously ADS-5102), the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease, with a pipeline of differentiated investigational programs, which includes: ADS-5102 in development for the treatment of multiple sclerosis walking impairment; and ADS-4101, a high-dose, modified release lacosamide in development for the treatment of partial onset seizures in patients with epilepsy. Adamas’ goal is to create and commercialize a new generation of neurological medicines intended to lessen the burden of disease on patients, caregivers and society. For more information about Adamas and its unique approach to developing medicines based on time-dependent biology, please visit www.adamaspharma.com.
Contact:
Media:
Terri Clevenger
Continuum Health Communications
203-227-0209
[email protected]
Investors:
Ashleigh Barreto
Director, Corporate Communications & Investor Relations
Adamas Pharmaceuticals, Inc.
510-450-3567
[email protected]
